Research Topics
Species | William SellersSummaryAffiliation: Harvard University Country: USA Publications
| Collaborators
|
Detail Information
Publications
The EZH2 polycomb transcriptional repressor--a marker or mover of metastatic prostate cancer?William R Sellers
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 2:349-50. 2002....- Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell lineJames DiRenzo
Department of Adult Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Res 62:89-98. 2002..Our studies suggest that the immortalization of basal epithelial cells of the mammary gland may be an early step in the initiation of a subset of breast cancers with a basal epithelial phenotype... - Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptorJames V Alvarez
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 66:3162-8. 2006..Thus, STAT3 is a critical mediator of the oncogenic effects of somatic EGFR mutations and targeting STAT3 may be an effective strategy for treating tumors characterized by these mutations... - From integrated genomics to tumor lineage dependencyLevi A Garraway
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 66:2506-8. 2006..Similar combined genomic approaches may be useful in other cancer types to learn how critical regulators of tumor lineage are linked to genomic alterations in cancer cells... 
Allele-specific amplification in cancer revealed by SNP array analysisThomas LaFramboise
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States of America
PLoS Comput Biol 1:e65. 2005..An R software package containing the methods described in this paper is freely available at http://genome.dfci.harvard.edu/~tlaframb/PLASQ...- Molecular determinants of the response of glioblastomas to EGFR kinase inhibitorsIngo K Mellinghoff
Department of Molecular and Medical Pharmacology and Medicine, David Geffen School of Medicine at the University of California, Los Angeles, Los Angeles 90095-1732, USA
N Engl J Med 353:2012-24. 2005..In vitro, coexpression of EGFRvIII and PTEN sensitized glioblastoma cells to erlotinib. CONCLUSIONS: Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors... - Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progressionJingrui Jiang
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 65:8968-74. 2005..Our results provide a model system to study the function of mutated EGFR and the differential effects of pharmacologic EGFR inhibition on the distinct mutant forms of this tyrosine kinase... - Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutantsHeidi Greulich
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, United States of America
PLoS Med 2:e313. 2005..The presence of mutations correlates with tumor sensitivity to the EGFR inhibitors erlotinib and gefitinib, but the transforming potential of specific mutations and their relationship to drug sensitivity have not been described... - Amplification and overexpression of prosaposin in prostate cancerShahriar Koochekpour
Department of Microbiology, Immunology, and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA
Genes Chromosomes Cancer 44:351-64. 2005.... - Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanomaLevi A Garraway
Department of Medical Oncology, and Melanoma Program in Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA
Nature 436:117-22. 2005..Together, these data suggest that MITF represents a distinct class of 'lineage survival' or 'lineage addiction' oncogenes required for both tissue-specific cancer development and tumour progression... - Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysisXiaojun Zhao
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Res 65:5561-70. 2005..EGFR amplification was shown to be independent of kinase domain mutational status... - Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosisRoss L Levine
Division of Hematology, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Cell 7:387-97. 2005..In vitro analysis demonstrated that JAK2V617F is a constitutively active tyrosine kinase... - Selective ablation of retinoblastoma protein function by the RET finger proteinMaja Krützfeldt
Centre for Cell and Molecular Biology, Chester Beatty Laboratories, 237 Fulham Road, SW3 6JB London, United Kingdom
Mol Cell 18:213-24. 2005..These findings provide precedent for a regulatory pathway that uncouples different Rb-dependent activities and thus silences specific cellular responses to Rb in a selective way... - Inferring loss-of-heterozygosity from unpaired tumors using high-density oligonucleotide SNP arraysRameen Beroukhim
Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
PLoS Comput Biol 2:e41. 2006..We have developed a method for analyzing high-density oligonucleotide SNP array data to accurately identify of regions of LOH and retention in tumors without the need for paired normal samples... - Development of an integrated prostate cancer research information systemWilliam K Oh
Lank Center for Genitourinary Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Clin Genitourin Cancer 5:61-6. 2006..In this article, we describe the design and implementation of a comprehensive prostate cancer database developed to collect, store, and access clinical, treatment, and outcomes data for research and clinical care... 
Major copy proportion analysis of tumor samples using SNP arraysCheng Li
Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute and Harvard School of Public Health, 3 Blackfan Circle, Boston, MA 02115, USA
BMC Bioinformatics 9:204. 2008..We have previously used Hidden Markov Models (HMM) to analyze SNP array data for inferring copy numbers and loss-of-heterozygosity (LOH) from paired normal and tumor samples and unpaired tumor samples...- PTEN nuclear localization is regulated by oxidative stress and mediates p53-dependent tumor suppressionChun Ju Chang
Molecular and Medical Pharmacology, UCLA School of Medicine, Los Angeles, CA 90095, USA
Mol Cell Biol 28:3281-9. 2008..Since tumor cells are constantly exposed to oxidative stress, our study elucidates the cooperative roles of nuclear PTEN with p53 in tumor suppression... - SNP panel identification assay (SPIA): a genetic-based assay for the identification of cell linesFrancesca Demichelis
Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
Nucleic Acids Res 36:2446-56. 2008.... 
Modeling genomic diversity and tumor dependency in malignant melanomaWilliam M Lin
Department of Medical Oncology, Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
Cancer Res 68:664-73. 2008..Genetically defined cell culture collections therefore offer a rich framework for systematic functional studies in melanoma and other tumors...- HER-2/neu expression is associated with high tumor cell proliferation and aggressive phenotype in a population based patient series of endometrial carcinomasIngeborg B Engelsen
Department of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway
Int J Oncol 32:307-16. 2008..These results motivate further clinical trials with trastuzumab based on HER-2/neu status in endometrial carcinomas... - Focal gains of VEGFA and molecular classification of hepatocellular carcinomaDerek Y Chiang
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA
Cancer Res 68:6779-88. 2008..Furthermore, the prevalence of VEGFA high-level gains in multiple tumor types suggests indications for clinical trials of antiangiogenic therapies... - Identification of prostate cancer modifier pathways using parental strain expression mappingQing Xu
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115
Proc Natl Acad Sci U S A 104:17771-6. 2007..Together, these data suggest that parental strain expression mapping can directly identify germ-line modifier pathways of relevance to human disease... - High-throughput oncogene mutation profiling in human cancerRoman K Thomas
Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
Nat Genet 39:347-51. 2007..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention... - Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domainJeffrey C Lee
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute Harvard Medical School, Boston, Massachusetts, United States of America
PLoS Med 3:e485. 2006..Missense mutations in the EGFR kinase domain, for example, have recently been identified in patients who showed clinical responses to EGFR kinase inhibitor therapy... - TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancerSven Perner
Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, EBRC 442A, 221 Longwood Avenue, Boston, MA 02115-6110, USA
Cancer Res 66:8337-41. 2006..The deletion as cause of TMPRSS2:ERG fusion is associated with clinical features for prostate cancer progression compared with tumors that lack the TMPRSS2:ERG rearrangement... - Lineage dependency and lineage-survival oncogenes in human cancerLevi A Garraway
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
Nat Rev Cancer 6:593-602. 2006..MITF and other lineage-survival genes therefore implicate lineage dependency (or lineage addiction) as a newly recognized mechanism that is affected by tumour genetic alterations... - EGFR gene mutations: a call for global x global views of cancerWilliam R Sellers
J Natl Cancer Inst 97:326-8. 2005 - Androgen-induced differentiation and tumorigenicity of human prostate epithelial cellsRaanan Berger
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA
Cancer Res 64:8867-75. 2004..These observations indicate that androgen receptor expression is oncogenic and addictive for the human prostate epithelium... - Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemiaMohamed Bentires-Alj
Cancer Biology Program, Department of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
Cancer Res 64:8816-20. 2004..Our data demonstrate that mutations in PTPN11 occur at low frequency in several human cancers, especially neuroblastoma and AML, and suggest that Shp2 may be a novel target for antineoplastic therapy... - mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathwaysPradip K Majumder
Department of Medical Oncology, Dana Farber Cancer Institute, and Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Nat Med 10:594-601. 2004.... - Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNPMarshall E Lieberfarb
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Res 63:4781-5. 2003..This organizational strategy revealed apparently distinct genetic subsets of prostate cancer... - Genome coverage and sequence fidelity of phi29 polymerase-based multiple strand displacement whole genome amplificationJ Guillermo Paez
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Nucleic Acids Res 32:e71. 2004..These results suggest that phi29MDA yields high fidelity, near-complete genome representation suitable for high resolution genetic analysis... - An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arraysXiaojun Zhao
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Res 64:3060-71. 2004..The simultaneous measurement of DNA copy number changes and loss of heterozygosity events by SNP arrays should strengthen our ability to discover cancer-causing genes and to refine cancer diagnosis... - EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapyJ Guillermo Paez
Departments of Medical Oncology and Cancer Biology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Science 304:1497-500. 2004..These results suggest that EGFR mutations may predict sensitivity to gefitinib... - TSC2 regulates VEGF through mTOR-dependent and -independent pathwaysJames B Brugarolas
Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Cancer Cell 4:147-58. 2003..This pathway may involve chromatin remodeling since the HDAC inhibitor Trichostatin A downregulates VEGF in TSC2(-/-) cells... - dChipSNP: significance curve and clustering of SNP-array-based loss-of-heterozygosity dataMing Lin
Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115, USA
Bioinformatics 20:1233-40. 2004..harvard.edu/complab/dchip/snp/ SUPPLEMENTARY INFORMATION: The breast cancer data are provided by Andrea L. Richardson, Zhigang C. Wang and James D. Iglehart... - A chemical genetic screen identifies inhibitors of regulated nuclear export of a Forkhead transcription factor in PTEN-deficient tumor cellsTweeny R Kau
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 4:463-76. 2003..Novel general export inhibitors were found that react with CRM1 as well as a number of compounds that inhibit PI3K/Akt signaling, among which are included multiple antagonists of calmodulin signaling... - Use of expression analysis to predict outcome after radical prostatectomyPhillip G Febbo
Department of Medical Oncology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02118, USA
J Urol 170:S11-9; discussion S19-20. 2003..A critical next step will be to try and validate such findings in larger independent datasets... - Overexpression, amplification, and androgen regulation of TPD52 in prostate cancerMark A Rubin
Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
Cancer Res 64:3814-22. 2004..In summary, these findings suggest that dysregulation of TPD52 by genomic amplification and androgen induction may play a role in prostate cancer progression... - Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograftAnat Bar-Shira
Genetic Institute, Tel Aviv Sourasky Medical Center, Tel Aviv 64239, Israel
Cancer Res 62:6803-7. 2002..Our data suggest these genes to be involved in advanced stages of prostate tumorigenesis and as such, they may serve as markers for tumor progression... - The biology and clinical relevance of the PTEN tumor suppressor pathwayIsabelle Sansal
Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
J Clin Oncol 22:2954-63. 2004..Akt kinase inhibitors are still in development; however, as a first test of this hypothesis, phase I and phase II trials of inhibitors of mTOR, namely, rapamycin and rapamycin analogs are underway... - Molecular characterization of the tumor microenvironment in breast cancerMinna Allinen
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA
Cancer Cell 6:17-32. 2004..Thus, chemokines may play a role in breast tumorigenesis by acting as paracrine factors... - A novel mechanism of gene regulation and tumor suppression by the transcription factor FKHRShivapriya Ramaswamy
Department of Adult Oncology and Department of Internal Medicine, Dana Farber Cancer Institute and Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
Cancer Cell 2:81-91. 2002..These data suggest that a novel mechanism of FKHR-mediated gene regulation is linked to its activity as a suppressor of tumor growth... - Analysis of androgen regulated homeobox gene NKX3.1 during prostate carcinogenesisCeren G Korkmaz
Department of Molecular Biosciences, and Biotechnology Centre of Oslo, University of Oslo, Oslo, Norway
J Urol 172:1134-9. 2004..1 might have a direct role in prostate carcinogenesis, possibly functioning as a tumor suppressor protein. Previous studies of the levels of NKX3.1 mRNA or protein in prostate cancer specimens have resulted in conflicting findings... - Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor typesIan Krop
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney Street, D740C, Boston, MA 02115, USA
Mol Cancer Res 2:489-94. 2004..Thus, silencing of HIN-1 expression and methylation of its promoter occurs in multiple human cancer types, suggesting that elimination of HIN-1 function may contribute to several forms of epithelial tumorigenesis... - PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signalingJuan Paez
Department of Adult Oncology, Dana-Farber Cancer Institute, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Treat Res 115:145-67. 2003 - Drug-sensitive FGFR2 mutations in endometrial carcinomaAmit Dutt
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana Farber Cancer Institute, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 105:8713-7. 2008..Inhibition of FGFR2 kinase activity in endometrial carcinoma cell lines bearing such FGFR2 mutations inhibits transformation and survival, implicating FGFR2 as a novel therapeutic target in endometrial carcinoma... - A 2-Mb critical region implicated in the microcephaly associated with terminal 1q deletion syndromeAnthony D Hill
Howard Hughes Medical Institute, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
Am J Med Genet A 143:1692-8. 2007..0-Mb microcephaly critical region including the 1q43-1q44 boundary and no more than 11 genes... - Gene expression correlates of clinical prostate cancer behaviorDinesh Singh
Department of Adult Oncology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Cancer Cell 1:203-9. 2002..These results support the notion that the clinical behavior of prostate cancer is linked to underlying gene expression differences that are detectable at the time of diagnosis... - Assessing the significance of chromosomal aberrations in cancer: methodology and application to gliomaRameen Beroukhim
Broad Institute, Massachusetts Institute of Technology and Harvard University, 7 Cambridge Center, Cambridge, MA 02142, USA
Proc Natl Acad Sci U S A 104:20007-12. 2007..Our results support the feasibility and utility of systematic characterization of the cancer genome... - Prostate intraepithelial neoplasia induced by prostate restricted Akt activation: the MPAKT modelPradip K Majumder
Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 100:7841-6. 2003..Thus, the MPAKT model may be useful in studying the role of Akt in prostate epithelial cell transformation and in the discovery of molecular markers relevant to human disease... - Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatmentPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco 94115-1711, USA
J Urol 170:S3-5. 2003 - A library of siRNA duplexes targeting the phosphoinositide 3-kinase pathway: determinants of gene silencing for use in cell-based screensAndrew C Hsieh
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA
Nucleic Acids Res 32:893-901. 2004..These data help to lay the foundation for genome-wide siRNA screens in mammalian cells... - Fourth International Conference on Innovations and Challenges in Prostate Cancer: Prevention, Detection and TreatmentPeter R Carroll
Department of Urology, University of California School of Medicine, San Francisco 94115-1711, USA
J Urol 172:S3-5. 2004 - High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogeneMaria I Torres-Arzayus
Division of Molecular and Cellular Oncology, Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
Cancer Cell 6:263-74. 2004..Knockdown of AIB1 expression in cultured AIB1-tg mammary tumor cells leads to reduced IGF-I mRNA levels and increased apoptosis, suggesting that an autocrine IGF-I loop underlies the mechanism of AIB1-induced oncogenesis... - p63 regulates commitment to the prostate cell lineageSabina Signoretti
Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
Proc Natl Acad Sci U S A 102:11355-60. 2005..Finally, in contrast with the prostate findings, analysis of the urothelium from rescued p63-/- chimeras shows that umbrella (superficial) cells can develop and be maintained independently from p63-positive basal and intermediate cells... - Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AMLJingrui Jiang
Department of Medical Oncology, Dana Farber Cancer Institute, 44 Binney St, D720C, Boston, MA 02115, USA
Blood 104:1855-8. 2004..These results suggest that mutations at N841 represent a significant new activating mutation in patients with AML and that patients with such mutations may respond to small-molecule FLT3 inhibitors such as PKC412... - BRAF mutation predicts sensitivity to MEK inhibitionDavid B Solit
Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, New York 10021, USA
Nature 439:358-62. 2006..These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype... - Akt-regulated pathways in prostate cancerPradip K Majumder
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
Oncogene 24:7465-74. 2005.... - Seventeenth Annual Pezcoller Symposium: molecular understanding of solid tumorsEnrico Mihich
Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY 14263, USA
Cancer Res 65:11251-4. 2005 - Validating cancer drug targetsJohn D Benson
Novartis Institutes for BioMedical Research, 250 Massachusetts Avenue, Cambridge, Massachusetts 02139, USA
Nature 441:451-6. 2006..Although the outcome of validation studies can guide cancer research programmes, strictly defined universal validation criteria have not been established... - Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencingRoman K Thomas
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
Nat Med 12:852-5. 2006..This technology can thereby facilitate accurate molecular diagnosis of heterogeneous cancer specimens and enable patient selection for targeted cancer therapies... - A Smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor-alpha signalingAlex Gaither
Oncology Disease Area and Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts 02139, USA
Cancer Res 67:11493-8. 2007..Mechanistic studies indicate that in this context, XIAP is a positive modulator of TNFalpha induction whereas cellular inhibitor of apoptosis protein 1 negatively regulates TNFalpha-mediated apoptosis...